Tech Company Financing Transactions
Intradigm Funding Round
Intradigm closed a $21.4 million Series B funding round on 1/7/2009. Backers included Lilly Ventures.
Transaction Overview
Company Name
Announced On
1/7/2009
Transaction Type
Venture Equity
Amount
$21,400,000
Round
Series B
Investors
Lilly Ventures (Lead Investor) (Bryan Dunnivant)
Proceeds Purpose
Intradigm will use Series B funds to advance its RNAi therapeutics platform, which is comprised of both its siRNA intellectual property, as well as its proprietary delivery technology, toward the development of systemic siRNA therapeutic candidates with an initial focus on cancer targets.intellectual property, as well as its RNAi Nanoplex (NPX) delivery technology, toward the development of systemic siRNA therapeutic candidates with an initial focus on cancer targets.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
21 Albemarle Street
London, W1S 4BS
UK
London, W1S 4BS
UK
Phone
Website
Email Address
Overview
Our Mission: To deliver the promise of RNA interference (RNAi) therapeutics for the treatment of human diseases with unmet medical needs through our advanced targeted systemic delivery technology with an initial focus on oncology therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Thomas Christély
Chief Financial Officer
Max Herrmann
Chief Scientific Officer
Klaus Giese
VP - Bus. Development
Tony Sedgwick
VP - R & D
Jorg Kaufmann
Browse more venture capital transactions:
Prev: 1/7/2009: Sentilla venture capital transaction
Next: 1/7/2009: TheInfoPro venture capital transaction
Share this article
News on VC Transactions
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs